Kite Pharma (NASDAQ:KITE) has earned an average rating of “Buy” from the twelve brokerages that are covering the stock, ARN reports. Two analysts have rated the stock with a hold recommendation and ten have given a buy recommendation to the company. The average 12 month price target among brokers that have issued a report on […]
